Wenbo Guo Selected Research

Drug Therapy (Chemotherapy)

1/2024	Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with a Diameter >8 Cm: A Retrospective Study.
1/2023	Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study.
11/2022	Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study.
4/2022	Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk.
1/2022	Elucidating minimal residual disease of paediatric B-cell acute lymphoblastic leukaemia by single-cell analysis.
10/2021	Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
1/2021	Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapy.
6/2020	Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wenbo Guo Research Topics

Disease

15	Hepatocellular Carcinoma (Hepatoma) 04/2024 - 05/2018
13	Neoplasms (Cancer) 04/2024 - 08/2018
3	Thrombosis (Thrombus) 04/2024 - 04/2022
2	Neuroinflammatory Diseases 03/2024 - 01/2023
2	Alzheimer Disease (Alzheimer's Disease) 01/2023 - 01/2022
2	Neoplasm Metastasis (Metastasis) 12/2021 - 08/2019
1	Hand-Foot Syndrome 04/2024
1	Vascular Diseases (Vascular Disease) 03/2024
1	Ischemic Stroke 03/2024
1	Dementia (Dementias) 06/2023
1	Pneumonia (Pneumonitis) 06/2023
1	Inflammation (Inflammations) 06/2023
1	Abdominal Pain (Pain, Abdominal) 01/2023
1	Infections 01/2023
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2022
1	Neutropenia 11/2022
1	Exanthema (Rash) 08/2022
1	Hypertension (High Blood Pressure) 08/2022
1	Nausea 08/2022
1	Cavernous Transformation Of Portal Vein 04/2022
1	Hypoxia (Hypoxemia) 01/2022
1	Residual Neoplasm 01/2022
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022
1	Liver Neoplasms (Liver Cancer) 07/2021
1	Endometriosis 03/2021
1	Adenomyosis 03/2021
1	Pain (Aches) 01/2021
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021
1	Body Weight (Weight, Body) 01/2021
1	Carcinogenesis 02/2019
1	Lung Neoplasms (Lung Cancer) 02/2019
1	Bacterial Infections (Bacterial Infection) 01/2019
1	Dihydropyrimidine Dehydrogenase Deficiency 05/2018
1	Fibrosis (Cirrhosis) 11/2016
1	Hematoma 01/2013
1	Rupture 01/2013
1	Hemorrhage 01/2013

Drug/Important Bio-Agent (IBA)

3	RNA (Ribonucleic Acid)IBA 03/2024 - 01/2021
3	Small Cytoplasmic RNAIBA 01/2024 - 01/2021
3	Immune Checkpoint InhibitorsIBA 12/2023 - 09/2021
3	Biomarkers (Surrogate Marker)IBA 11/2023 - 01/2021
3	lenvatinibIBA 01/2023 - 10/2021
2	atezolizumabIBA 01/2024 - 11/2022
2	anlotinibIBA 01/2023 - 01/2020
2	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2023
2	pembrolizumabIBA 08/2022 - 10/2021
2	Capsules (Microcapsules)IBA 12/2021 - 01/2013
1	Sorafenib (BAY 43-9006)FDA Link 04/2024
1	salvianolic acid CIBA 03/2024
1	Small Interfering RNA (siRNA)IBA 01/2024
1	Hormones (Hormone)IBA 01/2024
1	Bevacizumab (Avastin)FDA Link 01/2024
1	Competitive Endogenous RNAIBA 11/2023
1	Indicators and Reagents (Reagents)IBA 06/2023
1	Interleukin-10 (Interleukin 10)IBA 06/2023
1	baicalinIBA 06/2023
1	CytokinesIBA 06/2023
1	Arginine (L-Arginine)FDA Link 06/2023
1	16S Ribosomal RNAIBA 06/2023
1	Interleukin-6 (Interleukin 6)IBA 06/2023
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2023
1	Transaminases (Aminotransferases)IBA 01/2023
1	tislelizumabIBA 01/2023
1	Orlistat (Xenical)FDA Link 01/2023
1	Carboplatin (JM8)FDA LinkGeneric 11/2022
1	B7-H1 AntigenIBA 11/2022
1	3-hydroxy-5-estrane-17-carbonitrile (ACN)IBA 11/2022
1	130-nm albumin-bound paclitaxelIBA 11/2022
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 04/2022
1	Transcription Factors (Transcription Factor)IBA 01/2022
1	MicroRNAs (MicroRNA)IBA 01/2022
1	Caspase 8 (Caspase-8)IBA 01/2022
1	Cytochromes c (Cytochrome c)IBA 01/2022
1	Caspase 3 (Caspase-3)IBA 01/2022
1	LigandsIBA 12/2021
1	aristolochic acid I (aristolochic acid)IBA 07/2021
1	EsterasesIBA 01/2021
1	Aspartic Acid (Aspartate)FDA Link 01/2021
1	AntigensIBA 01/2021
1	Aflatoxin B1 (Aflatoxin B)IBA 01/2021
1	Aflatoxin M1 (Aflatoxin M)IBA 01/2021
1	Analgesics (Analgesic Drugs)IBA 01/2021
1	Glutamic Acid (Glutamate)FDA Link 01/2021
1	Gemcitabine FDA Link 01/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021
1	Cell-Free Nucleic AcidsIBA 01/2021
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2021
1	Coal (Coals)IBA 02/2019
1	shuanglongIBA 02/2019
1	Anti-Infective Agents (Microbicides)IBA 01/2019
1	FlavonoidsIBA 08/2018
1	tetramethylpyrazineIBA 08/2018
1	UracilIBA 05/2018
1	dihydrouracilIBA 05/2018
1	Fluorouracil (Carac)FDA LinkGeneric 05/2018
1	CreatinineIBA 01/2013

Therapy/Procedure

12	Therapeutics 04/2024 - 01/2013
8	Drug Therapy (Chemotherapy) 01/2024 - 06/2020
1	Uterine Artery Embolization 03/2021
1	Folfox protocol 06/2020